Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGA trial of ctDNA-guided omission of adjuvant CAPOX in resected colon cancer
jRCT1031200006Phase 3Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and oxaliplatin in colon cancer (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Disease-free survival. Started Jul 2020; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on jRCT1031200006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031200006.